Global Cord Blood (NYSE:CO) Coverage Initiated at StockNews.com

Stock analysts at StockNews.com began coverage on shares of Global Cord Blood (NYSE:CO) in a note issued to investors on Wednesday. The firm set a “strong-buy” rating on the medical research company’s stock.

Global Cord Blood Price Performance

Shares of CO opened at $1.35 on Wednesday. Global Cord Blood has a 1 year low of $2.03 and a 1 year high of $5.50. The firm has a market cap of $164.09 million, a PE ratio of 2.11 and a beta of 0.16. The stock’s fifty day moving average price is $1.52 and its two-hundred day moving average price is $1.35.

Hedge Funds Weigh In On Global Cord Blood

A number of institutional investors have recently added to or reduced their stakes in the business. Northern Trust Corp purchased a new stake in Global Cord Blood during the 2nd quarter valued at about $96,000. Natixis Advisors L.P. boosted its stake in Global Cord Blood by 5.6% during the 2nd quarter. Natixis Advisors L.P. now owns 199,880 shares of the medical research company’s stock valued at $592,000 after purchasing an additional 10,550 shares during the last quarter. Finally, Moneta Group Investment Advisors LLC boosted its stake in Global Cord Blood by 99,844.5% during the 4th quarter. Moneta Group Investment Advisors LLC now owns 26,093,520 shares of the medical research company’s stock valued at $77,957,000 after purchasing an additional 26,067,412 shares during the last quarter.

About Global Cord Blood

Global Cord Blood operates as a holding company, which engages in the provision of cord blood banking services. It provides cord blood processing and storage service. The company also offers cord blood collection, laboratory testing, hematopoietic stem cell processing and stem cell storage services. The firm preserves cord blood units donated by the public and provides matching services on such donated units and deliver matching units to patients in need of transplants.